The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | DNA-PKcs inhibition activates innate immunity in small cell lung cancer
Triparna Sen, PhD, The Ohio State University, Columbus, OH, discusses a preclinical study targeting DNA-PKcs, a family of DNA damage response inhibitors, in small cell lung cancer (SCLC), which is the most aggressive form of lung cancer characterized by high genomic instability. SCLC expresses the DNA-PKcs gene more than any other solid tumor and that targeting this gene with small molecule inhibitors, alone or in combination with immune checkpoint blockade, was effective in cell line and mouse models by activating the innate immune response pathway. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
